ArticleFunctional & integrative genomics2025
CircNOX4 promotes proliferation and resistance by regulating the hsa-miR-6884-5p/YWHAG Axis and ERK signaling pathway in cholangiocarcinoma.
Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- YWHAG overexpression correlates with an immune-desert microenvironment and poor prognosis in laryngeal squamous cell carcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The biological function of circular RNAs (circRNAs) has been increasingly implicated in tumor drug resistance. However, their role in intrahepatic cholangiocarcinoma (ICC) remains poorly understood, and the underlying mechanisms are largely unexplored. In this study, we identified a key circRNA, circNOX4, through data mining and experimental validation in ICC. We found that circNOX4 was significantly upregulated in ICC tissues and its expression correlated with advanced clinicopathological features. Functional assays demonstrated that circNOX4 promoted ICC cell proliferation and tumor growth both in vitro and in vivo. Mechanistically, circNOX4 acted as a molecular sponge for hsa-miR-6884-5p, thereby upregulating YWHAG expression. YWHAG, in turn, interacted with RAF1, enhancing its phosphorylation and activating the ERK signaling pathway. This led to the nuclear translocation of phosphorylated ERK and subsequent promotion of ICC progression. Furthermore, we found that circNOX4 attenuated the anti-tumor efficacy of Trametinib. In summary, circNOX4 contributes to ICC progression and drug resistance through the hsa-miR-6884-5p/YWHAG/ERK axis, and may serve as a potential diagnostic marker, prognostic indicator, and therapeutic target in ICC.
Indexed as
Identifiers
40736609What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.